Sebaceous neoplasia and the Muir-Torre syndrome: Important connections with clinical implications

Histopathology

Volumn 56, Issue 1, 2010, Pages 133-147

  Shalin, Sara C ^a   Lyle, Stephen ^b   Calonje, Eduardo ^c   Lazar, Alexander J F ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Mismatch repair deficiency; Muir Torre syndrome; Sebaceoma; Sebaceous adenoma; Sebaceous carcinoma; Sebaceous hyperplasia

Indexed keywords

ADIPOPHILIN; ANDROGEN RECEPTOR; BETA CATENIN; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; FRAGILE HISTIDINE TRIAD PROTEIN; KI 67 ANTIGEN; LYMPHOID ENHANCER FACTOR 1; PODOPLANIN; PROTEIN BCL 2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

ADENOMA; CANCER DIAGNOSIS; CARCINOGENESIS; CHEMOSURGERY; DIFFERENTIAL DIAGNOSIS; ENUCLEATION; EPITHELIUM TUMOR; EXCISION; EYELID CARCINOMA; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MUIR TORRE SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEBACEOMA; SEBACEOUS CARCINOMA; SEBACEOUS GLAND ADENOMA; SEBACEOUS GLAND HYPERPLASIA; SEBACEOUS GLAND TUMOR;

ADENOCARCINOMA, SEBACEOUS; ADENOMA; HUMANS; MUIR-TORRE SYNDROME; SEBACEOUS GLAND NEOPLASMS;

EID: 73449120742     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03454.x     Document Type: Review

References (108)

1. Li M. Normal skin. In Mills SE ed. Histology for pathologist. Philadelphia : Lippincott, Williams and Wilkins, 2007 3 28.
2. Danby FW. Why we have sebaceous glands. J. Am. Acad. Dermatol. 2005 52 1071 1072.
3. Zouboulis CC, Baron JM, Bohm M et al. Frontiers in sebaceous gland biology and pathology. Exp. Dermatol. 2008 17 542 551.
4. Bayer-Garner IB, Givens V, Smoller B. Immunohistochemical staining for androgen receptors: a sensitive marker of sebaceous differentiation. Am. J. Dermatopathol. 1999 21 426 431.
5. Bieniek R, Lazar AJ, Photopoulos C, Lyle S. Sebaceous tumours contain a subpopulation of cells expressing the keratin 15 stem cell marker. Br. J. Dermatol. 2007 156 378 380.
6. Misago N, Narisawa Y. Cytokeratin 15 expression in neoplasms with sebaceous differentiation. J. Cutan. Pathol. 2006 33 634 641.
7. Wang WP, Wang WS, Tsai YC. Multiple tiny ectopic sebaceous glands discovered throughout entire esophageal tract. Dig. Dis. Sci. 2009 54 2754 2757.
8. Belousova IE, Kazakov DV, Michal M. Ectopic sebaceous glands in the vagina. Int. J. Gynecol. Pathol. 2005 24 193 195.
9. Harada A, Tatsumi Y, Matsumoto T, Tani T, Nishida H, Katsura K. Ectopic sebaceous glands. Gastrointest. Endosc. 2004 60 97.
10. Robledo MC, Vazquez JJ, Contreras-Mejuto F, Lopez-Garcia G. Sebaceous glands and hair follicles in the cervix uteri. Histopathology 1992 21 278 280.
11. Wolff M, Rosai J, Wright DH. Sebaceous glands within the thymus: report of three cases. Hum. Pathol. 1984 15 341 343.
12. Batistatou A, Panelos J, Zioga A, Charalabopoulos KA. Ectopic modified sebaceous glands in human penis. Int. J. Surg. Pathol. 2006 14 355 356.
13. Prioleau PG, Santa Cruz DJ. Sebaceous gland neoplasia. J. Cutan. Pathol. 1984 11 396 414.
14. Zouboulis CC, Boschnakow A. Chronological ageing and photoageing of the human sebaceous gland. Clin. Exp. Dermatol. 2001 26 600 607. (Pubitemid 32989585)
15. Pang SM, Chau YP. Cyclosporin-induced sebaceous hyperplasia in renal transplant patients. Ann. Acad. Med. Singapore 2005 34 391 393.
16. de Berker DA, Taylor AE, Quinn AG, Simpson NB. Sebaceous hyperplasia in organ transplant recipients: shared aspects of hyperplastic and dysplastic processes? J. Am. Acad. Dermatol. 1996 35 696 699.
17. Singh RS, Grayson W, Redston M et al. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am. J. Surg. Pathol. 2008 32 936 942.
18. Cesinaro AM, Ubiali A, Sighinolfi P, Trentini GP, Gentili F, Facchetti F. Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer. Am. J. Dermatopathol. 2007 29 351 358.
19. Spraul CW, Jakobczyk-Zmija MJ, Lang GK. Sebaceous hyperplasia of the lower eyelid. Klin. Monatsbl. Augenheilkd. 1999 215 319 320.
20. Ferguson JW, Geary CP, MacAlister AD. Sebaceous cell adenoma. Rare intra-oral occurrence of a tumour which is a frequent marker of Torre's syndrome. Pathology 1987 19 204 208.
21. Welch KC, Papadimitriou JC, Morales R, Wolf JS. Sebaceous adenoma of the parotid gland in a 2-year-old male. Otolaryngol. Head Neck Surg. 2007 136 672 673.
22. Terrell S, Wetter R, Fraga G, Kestenbaum T, Aires DJ. Penile sebaceous adenoma. J. Am. Acad. Dermatol. 2007 57 S42 S43.
23. Rulon DB, Helwig EB. Cutaneous sebaceous neoplasms. Cancer 1974 33 82 102.
24. Kazakov DV, Kutzner H, Spagnolo DV, Rutten A, Mukensnabl P, Michal M. Discordant architectural and cytological features in cutaneous sebaceous neoplasms - a classification dilemma: report of 5 cases. Am. J. Dermatopathol. 2009 31 31 36.
25. Resnik KS. Classifying neoplasms with sebaceous differentiation - a reviewer's comments. Am. J. Dermatopathol. 2009 31 94 96.
26. Lazar AJ, Lyle S, Calonje E. Sebaceous neoplasia and Torre-Muir syndrome. Curr. Diagn. Pathol. 2007 13 301 319.
27. Troy JL, Ackerman AB. Sebaceoma. A distinctive benign neoplasm of adnexal epithelium differentiating toward sebaceous cells. Am. J. Dermatopathol. 1984 6 7 13.
28. Misago N, Mihara I, Ansai S, Narisawa Y. Sebaceoma and related neoplasms with sebaceous differentiation: a clinicopathologic study of 30 cases. Am. J. Dermatopathol. 2002 24 294 304.
29. Misago N, Suse T, Uemura T, Narisawa Y. Basal cell carcinoma with sebaceous differentiation. Am. J. Dermatopathol. 2004 26 298 303. (Pubitemid 38989026)
30. Kazakov DV, Kutzner H, Rutten A, Mukensnabl P, Michal M. Carcinoid-like pattern in sebaceous neoplasms: another distinctive, previously unrecognized pattern in extraocular sebaceous carcinoma and sebaceoma. Am. J. Dermatopathol. 2005 27 195 203.
31. Misago N, Narisawa Y. Rippled-pattern sebaceoma. Am. J. Dermatopathol. 2001 23 437 443.
32. Nielsen TA, Maia-Cohen S, Hessel AB, Xie DL, Pellegrini AE. Sebaceous neoplasm with reticulated and cribriform features: a rare variant of sebaceoma. J. Cutan. Pathol. 1998 25 233 235.
33. Dinneen AM, Mehregan DR. Sebaceous epithelioma: a review of twenty-one cases. J. Am. Acad. Dermatol. 1996 34 47 50.
34. Sachez Yus E, Requena L, Simon P, del Rio E. Sebomatricoma: a unifying term that encompasses all benign neoplasms with sebaceous differentiation. Am. J. Dermatopathol. 1995 17 213 221.
35. Leboeuf NR, Mahalingam M. Acanthomatous superficial sebaceous hamartoma? A study of six cases with clarification of the nomenclature. J. Cutan. Pathol. 2007 34 865 870.
36. Friedman KJ, Boudreau S, Farmer ER. Superficial epithelioma with sebaceous differentiation. J. Cutan. Pathol. 1987 14 193 197.
37. Lee MJ, Kim YC, Lew W. A case of superficial epithelioma with sebaceous differentiation. Yonsei Med. J. 2003 44 347 350.
38. Steffen C. Mantleoma. A benign neoplasm with mantle differentiation. Am. J. Dermatopathol. 1993 15 306 310.
39. Collins GL, Somach S, Morgan MB. Histomorphologic and immunophenotypic analysis of fibrofolliculomas and trichodiscomas in Birt-Hogg-Dube syndrome and sporadic disease. J. Cutan. Pathol. 2002 29 529 533.
40. Dores GM, Curtis RE, Toro JR, Devesa SS, Fraumeni JF Jr. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. Cancer 2008 113 3372 3381.
41. Dowd MB, Kumar RJ, Sharma R, Murali R. Diagnosis and management of sebaceous carcinoma: an Australian experience. ANZ J. Surg. 2008 78 158 163.
42. Song A, Carter KD, Syed NA, Song J, Nerad JA. Sebaceous cell carcinoma of the ocular adnexa: clinical presentations, histopathology, and outcomes. Ophthal. Plast. Reconstr. Surg. 2008 24 194 200.
43. Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer 2009 115 158 165.
44. Xu XL, Li B, Sun XL et al. Eyelid neoplasms in the Beijing Tongren Eye Centre between 1997 and 2006. Ophthalmic Surg. Lasers Imaging 2008 39 367 372.
45. Deprez M, Uffer S. Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature. Am. J. Dermatopathol. 2009 31 256 262.
46. Gonzalez-Fernandez F, Kaltreider SA, Patnaik BD et al. Sebaceous carcinoma. Tumor progression through mutational inactivation of p53. Ophthalmology 1998 105 497 506.
47. Buitrago W, Joseph AK. Sebaceous carcinoma: the great masquerader: emerging concepts in diagnosis and treatment. Dermatol. Ther. 2008 21 459 466.
48. Rao NA, Hidayat AA, McLean IW, Zimmerman LE. Sebaceous carcinomas of the ocular adnexa: a clinicopathologic study of 104 cases, with five-year follow-up data. Hum. Pathol. 1982 13 113 122.
49. Pereira PR, Odashiro AN, Rodrigues-Reyes AA, Correa ZM, de Souza Filho JP, Burnier MN Jr. Histopathological review of sebaceous carcinoma of the eyelid. J. Cutan. Pathol. 2005 32 496 501.
50. Cibull TL, Thomas AB, Badve S, Billings SD. Sebaceous carcinoma of the nipple. J. Cutan. Pathol. 2008 35 608 610.
51. Omura NE, Collison DW, Perry AE, Myers LM. Sebaceous carcinoma in children. J. Am. Acad. Dermatol. 2002 47 950 953.
52. Wick MR, Goellner JR, Wolfe JT 3rd., Su WP. Adnexal carcinomas of the skin. II. Extraocular sebaceous carcinomas. Cancer 1985 56 1163 1172.
53. Metze D, Soyer HP, Zelger B et al. Expression of a glycoprotein of the carcinoembryonic antigen family in normal and neoplastic sebaceous glands. Limited role of carcinoembryonic antigen as a sweat gland marker. J. Am. Acad. Dermatol. 1996 34 735 744.
54. Izumi M, Tang X, Chiu CS et al. Ten cases of sebaceous carcinoma arising in nevus sebaceus. J. Dermatol. 2008 35 704 711.
55. Izumi M, Mukai K, Nagai T et al. Sebaceous carcinoma of the eyelids: thirty cases from Japan. Pathol. Int. 2008 58 483 488.
56. Muthusamy K, Halbert G, Roberts F. Immunohistochemical staining for adipophilin, perilipin and TIP47. J. Clin. Pathol. 2006 59 1166 1170.
57. Sramek B, Lisle A, Loy T. Immunohistochemistry in ocular carcinomas. J. Cutan. Pathol. 2008 35 641 646.
58. Fan YS, Carr RA, Sanders DS, Smith AP, Lazar AJ, Calonje E. Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma. Histopathology 2007 51 80 86.
59. Yang HM, Cabral E, Dadras SS, Cassarino DS. Immunohistochemical expression of D2-40 in benign and malignant sebaceous tumors and comparison to basal and squamous cell carcinomas. Am. J. Dermatopathol. 2008 30 549 554.
60. Heyl J, Mehregan D. Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas. J. Cutan. Pathol. 2008 35 40 45.
61. Cabral ES, Auerbach A, Killian JK, Barrett TL, Cassarino DS. Distinction of benign sebaceous proliferations from sebaceous carcinomas by immunohistochemistry. Am. J. Dermatopathol. 2006 28 465 471.
62. Abdel-Rahman WM, Peltomaki P. Lynch syndrome and related familial colorectal cancers. Crit. Rev. Oncog. 2008 14 1 22. discussion 23-31.
63. Lucci-Cordisco E, Zito I, Gensini F, Genuardi M. Hereditary nonpolyposis colorectal cancer and related conditions. Am. J. Med. Genet. A 2003 122A 325 334.
64. Hsieh P, Yamane K. DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech. Ageing Dev. 2008 129 391 407.
65. Yuen ST, Chan TL, Ho JW et al. Germline, somatic and epigenetic events underlying mismatch repair deficiency in colorectal and HNPCC-related cancers. Oncogene 2002 21 7585 7592.
66. Kruse R, Rutten A, Hosseiny-Malayeri HR et al. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation. J. Invest. Dermatol. 2001 116 463 465.
67. Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J. Am. Acad. Dermatol. 1995 33 90 104.
68. Cohen PR, Kohn SR, Davis DA, Kurzrock R. Muir-Torre syndrome. Dermatol. Clin. 1995 13 79 89.
69. Jones B, Oh C, Mangold E, Egan CA. Muir-Torre syndrome: diagnostic and screening guidelines. Australas. J. Dermatol. 2006 47 266 269.
70. Kruse R, Ruzicka T. DNA mismatch repair and the significance of a sebaceous skin tumor for visceral cancer prevention. Trends Mol. Med. 2004 10 136 141.
71. Orta L, Klimstra DS, Qin J et al. Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics. Am. J. Surg. Pathol. 2009 33 934 944.
72. Abbas O, Mahalingam M. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm. J. Cutan. Pathol. 2009 36 613 619.
73. Marcus VA, Madlensky L, Gryfe R et al. Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am. J. Surg. Pathol. 1999 23 1248 1255.
74. Lindor NM, Burgart LJ, Leontovich O et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J. Clin. Oncol. 2002 20 1043 1048.
75. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl Cancer Inst. 2004 96 261 268. (Pubitemid 38256271)
76. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998 58 5248 5257.
77. Nishizawa A, Nakanishi Y, Sasajima Y, Yamazaki N, Yamamoto A. Muir-Torre syndrome with intriguing squamous lesions: a case report and review of the literature. Am. J. Dermatopathol. 2006 28 56 59.
78. Paraf F, Sasseville D, Watters AK et al. Clinicopathological relevance of the association between gastrointestinal and sebaceous neoplasms: the Muir-Torre syndrome. Hum. Pathol. 1995 26 422 427.
79. Rishi K, Font RL. Sebaceous gland tumors of the eyelids and conjunctiva in the Muir-Torre syndrome: a clinicopathologic study of five cases and literature review. Ophthal. Plast. Reconstr. Surg. 2004 20 31 36.
80. Tsalis K, Blouhos K, Vasiliadis K, Tsachalis T, Angelopoulos S, Betsis D. Sebaceous gland tumors and internal malignancy in the context of Muir-Torre syndrome. A case report and review of the literature. World J. Surg. Oncol. 2006 4 8.
81. Mangold E, Pagenstecher C, Leister M et al. A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome. J. Med. Genet. 2004 41 567 572.
82. Chhibber V, Dresser K, Mahalingam M. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome. Mod. Pathol. 2008 21 159 164.
83. Rutten A, Burgdorf W, Hugel H et al. Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study. Am. J. Dermatopathol. 1999 21 405 413.
84. Abbott JJ, Hernandez-Rios P, Amirkhan RH, Hoang MP. Cystic sebaceous neoplasms in Muir-Torre syndrome. Arch. Pathol. Lab. Med. 2003 127 614 617.
85. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am. J. Pathol. 2001 158 527 535.
86. Ponti G, Venesio T, Losi L et al. BRAF mutations in multiple sebaceous hyperplasias of patients belonging to MYH-associated polyposis pedigrees. J. Invest. Dermatol. 2007 127 1387 1391.
87. Barnetson RA, Devlin L, Miller J et al. Germline mutation prevalence in the base excision repair gene, MYH, in patients with endometrial cancer. Clin. Genet. 2007 72 551 555.
88. Ajith Kumar VK, Gold JA, Mallon E, Thomas S, Hodgson SV. Sebaceous adenomas in an MYH associated polyposis patient of Indian (Gujarati) origin. Fam. Cancer 2008 7 187 189.
89. Ponti G, Ponz de Leon M, Maffei S et al. Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations. Clin. Genet. 2005 68 442 447.
90. Reitmair AH, Redston M, Cai JC et al. Spontaneous intestinal carcinomas and skin neoplasms in Msh2-deficient mice. Cancer Res. 1996 56 3842 3849.
91. Edelmann W, Yang K, Umar A et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 1997 91 467 477.
92. Watt FM, Collins CA. Role of beta-catenin in epidermal stem cell expansion, lineage selection, and cancer. Cold Spring Harb. Symp. Quant. Biol. 2008 73 503 512.
93. Lazar AJ, Calonje E, Grayson W et al. Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin. J. Cutan. Pathol. 2005 32 148 157.
94. Chan EF, Gat U, McNiff JM, Fuchs E. A common human skin tumour is caused by activating mutations in beta-catenin. Nat. Genet. 1999 21 410 413.
95. Niemann C, Unden AB, Lyle S, Zouboulis Ch C, Toftgard R, Watt FM. Indian hedgehog and beta-catenin signaling: role in the sebaceous lineage of normal and neoplastic mammalian epidermis. Proc. Natl Acad. Sci. USA 2003 100 (Suppl. 1 11873 11880.
96. Niemann C, Owens DM, Hulsken J, Birchmeier W, Watt FM. Expression of DeltaNLef1 in mouse epidermis results in differentiation of hair follicles into squamous epidermal cysts and formation of skin tumours. Development 2002 129 95 109.
97. Niemann C, Owens DM, Schettina P, Watt FM. Dual role of inactivating Lef1 mutations in epidermis: tumor promotion and specification of tumor type. Cancer Res. 2007 67 2916 2921.
98. Takeda H, Lyle S, Lazar AJ, Zouboulis CC, Smyth I, Watt FM. Human sebaceous tumors harbor inactivating mutations in LEF1. Nat. Med. 2006 12 395 397.
99. Zanesi N, Croce CM. Fragile histidine triad gene and skin cancer. Eur. J. Dermatol. 2001 11 401 404.
100. Fong LY, Fidanza V, Zanesi N et al. Muir-Torre-like syndrome in Fhit-deficient mice. Proc. Natl Acad. Sci. USA 2000 97 4742 4747.
101. Huber O, Weiske J. Beta-catenin takes a HIT. Cell Cycle 2008 7 1326 1331.
102. Weiske J, Albring KF, Huber O. The tumor suppressor Fhit acts as a repressor of beta-catenin transcriptional activity. Proc. Natl Acad. Sci. USA 2007 104 20344 20349.
103. Goldberg M, Rummelt C, Foja S, Holbach LM, Ballhausen WG. Different genetic pathways in the development of periocular sebaceous gland carcinomas in presumptive Muir-Torre syndrome patients. Hum. Mutat. 2006 27 155 162.
104. Holbach LM, von Moller A, Decker C, Junemann AG, Rummelt-Hofmann C, Ballhausen WG. Loss of fragile histidine triad (FHIT) expression and microsatellite instability in periocular sebaceous gland carcinoma in patients with Muir-Torre syndrome. Am. J. Ophthalmol. 2002 134 147 148.
105. Benjamin CL, Ananthaswamy HN. p53 and the pathogenesis of skin cancer. Toxicol. Appl. Pharmacol. 2007 224 241 248.
106. Das P, Kotilingam D, Korchin B et al. High prevalence of p53 exon 4 mutations in soft tissue sarcoma. Cancer 2007 109 2323 2333.
107. Blanpain C, Fuchs E. Epidermal homeostasis: a balancing act of stem cells in the skin. Nat. Rev. Mol. Cell Biol. 2009 10 207 217.
108. Watt FM, Lo Celso C, Silva-Vargas V. Epidermal stem cells: an update. Curr. Opin. Genet. Dev. 2006 16 518 524.